Mangalam Drugs & Organics has notified the stock exchanges of a forthcoming board meeting, scheduled for Thursday, May 14, 2026, at its registered office located at 3rd Floor, Rupam Building, 239, P.D'Mello Road, Near G.P.O., Mumbai, Maharashtra – 400001. The intimation was filed on May 6, 2026, under reference number MDOL/CS-SE/2026-27/005, pursuant to Regulation 29 and other applicable provisions of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Agenda for the Board Meeting

The primary business to be transacted at the upcoming board meeting is outlined below:

The board will consider, approve, and take on record the Audited Financial Results — both standalone and consolidated — for the quarter and year ended March 31, 2026.

Trading Window Closure

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct for prevention of insider trading, the trading window for dealing in the securities of the company has been closed for Directors, Officers, and designated employees. Key details of the trading window closure are as follows:

• Closure commenced: April 1, 2026
• Closure ends: 48 hours after the announcement or declaration of the audited financial results for the quarter and year ended March 31, 2026
• Applicable persons: Directors, Officers, and designated employees covered under the company's internal code of conduct

The closure of the trading window has been duly communicated to all designated persons covered by the code.

Signatory

The board meeting intimation has been signed by Govardhan M. Dhoot, Managing Director of Mangalam Drugs & Organics, with DIN: 01240086, and was digitally authenticated on May 6, 2026.

Mangalam drugs & organics Limited has filed a revised disclosure with BSE and NSE regarding the resignation of its Company Secretary & Compliance Officer, following communication from BSE about discrepancies in the earlier submission.

Regulatory Filing Details

The company submitted the revised disclosure on April 17, 2026, under reference number MDOL/CS-SE/2026-27/004, addressing the requirements of Regulation 30 of SEBI (LODR) Regulations, 2015. The filing was signed by Chairman & Managing Director Govardhan M. Dhoot and submitted to both stock exchanges.

Resignation Details

Ms. Anuradha Pandey tendered her resignation from the position of Company Secretary & Compliance Officer effective March 29, 2026. The resignation was formally submitted through a letter dated January 2, 2026, where Pandey cited her decision to pursue opportunities that align more closely with her long-term career goals and aspirations.

Administrative Oversight Acknowledged

The company explained that the resignation disclosure could not be submitted within the prescribed timeline of 7 days from the effective date due to an inadvertent administrative oversight. This resulted in the timeline for filing the mandatory disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 not being tracked appropriately.

The revised submission includes detailed documentation as required under SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015 and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Transition and Cooperation

In her resignation letter, Pandey expressed gratitude for the opportunities provided during her tenure and committed to ensuring a smooth transition of responsibilities. She offered her best cooperation during the notice period to facilitate continuity in operations and assist in training her successor.

The company has complied with SEBI circular requirements by providing detailed reasons for the resignation and acknowledging the procedural delay in filing the mandatory disclosure.